Centre for Biomarker Research in Medicine COMET Competence Centre for Excellent Technologies
Why Biomarker Research? early diagnosis, often before manifestation identification of at-risk patients for new cost-effective prevention concepts personalised therapy and therapy monitoring new diagnostic tests with high precision, fast analysis and low costs patient biobanking/analysis result sample basic research biomarkers targets for therapy 2
Vision Medical Vision CBmed aims to provide clinicians with easy to use, targeted, minimally invasive biomarkers for better diagnosis, therapy and monitoring of their patients Scientific Vision CBmed aims to combine different "-omics" technologies and advanced bioinformatics analyses for the fast identification of novel biomarkers but also to validate existing candidate biomarkers. Economic Vision CBmed aims to provide the necessary infrastructure for successful biomarker research and their translation into marketable products. 3
Aim & Objectives The overall aim of CBmed is to develop, validate and translate medical biomarkers for clinical practice. In cooperation with academic and industry partners the CBmed will be able to meet the following objectives: Take systematic biomarker research to the next level Build a strong network of research and industry partners Strategic planning based on industry and science Work on an international level Support gender aspects in research and management Efficient management 4
Cooperative Biomarker Research The biomarker research strategy at CBmed aims to establish longterm strategic partnerships with companies: access to the largest European Biobank Graz (>5 M samples) access to various clinical institutes and medical disciplines as well as biomarker research competence access to a broad national and European network of biomarker research (eg. BBMRI) access to specific clinical cohorts (clinical data, function tests, blood, serum, DNA, tissue) This cooperation offers a unique opportunity for industrial business development. 5
Scientific Programme 6
Industry Partners CBmed partners funded by K1 center non K-area 9.3 mio. 8.7 mio. additional commitment 3.8 Mio. Omnignostica total: 21.8 mio. 7
Shareholders Lead Partner 8
Scientific Partners Scientific partners: Biobanking and Biomolecular Resources Research Infrastructure- BBMRI (Frankreich) Austrian Breast & Colorectal Cancer Study Group- ABCSG (Ö) Ludwig Boltzmann Institut für experimentelle und klinische Traumatologie (Ö) Central European Society for Anticancer Drug Research- CESAR (Ö) Univ. Innsbruck (Ö) Know-Center (Ö) Secure Business Austria- SBA (Ö) Max-Planck-Institut für Molekulare Genetik (DE) Dahlem Center for Genome Research and Systems Biology (DE) Univ. München (DE) Univ. Jena (DE) Univ. of Queensland (Australien) Univ. of Iceland (Island) Univ. of Miami (USA) Univ. of Zagreb (Kroatien) Univ. of Uppsala (Schweden) Univ. of Toronto (Kanada) Associated scientific partners: National Institute of Health and Medical Research- INSERM (Frankreich) National Centre for Genomic Analysis- CNAG (Spanien) Deutsches Rheuma-Forschungszentrum Berlin- DRFZ (DE) Hebrew University Medical Centers (Israel) Freie Universität Berlin (DE) Univ. of Coventry (UK) Univ. of Sheffield (UK) 9
Organisational Structure General Assembly board of shareholders CEO - F Area 1 manager Area 2 manager CEO - S Area 3 manager Management Team (Project/Area Management, Office Management, Finance & Controlling, IPR, HR, Marketing, IT) International Ethical Advisory Board national and international ethics experts International Strategy Advisory Board International experts from industry and science Consortium Board Scientific and company partners, funding body, CEOs Area 1 Data & Technologies Projects Project Managers Area 2 Cancer Projects Project Managers Area 3 Metabolism & Inflammation Projects Project Managers 10
Timeline 2013 2014 1st half year 2014 2nd half year 2015 M1 Initiation, Partner acquisition Application Submission: 04.12.2013 M2 Detailed planning Preparation for hearing FFG Hearing: 18.06. 2014 Jury Decision: 09.07.2014 M3 Partner negotiations, Organisational structure CBmed Start CBmed: 01.01.2015 11
CONTACTS Univ.-Prof. Dr.med. Thomas Pieber (thomas.pieber@medunigraz.at) Dr. Selma Mautner (selma.mautner@medunigraz.at) Dr. Carolin Auer (carolin.auer@medunigraz.at) 12